Cyclacel Pharmaceuticals (NASDAQ:CYCC) Coverage Initiated by Analysts at StockNews.com

Stock analysts at StockNews.com started coverage on shares of Cyclacel Pharmaceuticals (NASDAQ:CYCC) in a research report issued to clients and investors on Monday. The brokerage set a “sell” rating on the biotechnology company’s stock.

Cyclacel Pharmaceuticals Price Performance

CYCC stock opened at $0.27 on Monday. The stock has a market capitalization of $1.69 million, a P/E ratio of -0.03 and a beta of 0.28. Cyclacel Pharmaceuticals has a fifty-two week low of $0.26 and a fifty-two week high of $4.00. The business has a 50-day moving average of $0.33 and a 200-day moving average of $0.50.

Insider Transactions at Cyclacel Pharmaceuticals

In other news, CEO David E. Lazar sold 194,628,820 shares of the business’s stock in a transaction on Wednesday, February 26th. The shares were sold at an average price of $0.03, for a total value of $5,838,864.60. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Company insiders own 23.97% of the company’s stock.

Cyclacel Pharmaceuticals Company Profile

Cyclacel Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases in the United States, the United Kingdom, and internationally. The company's lead product includes fadraciclib, a cyclin dependent kinase Inhibitors (CDK) that is in Phase 1/2 clinical trial for the treatment of solid tumors and hematological malignancies, as well as in combination with venetoclax to treat relapsed or refractory chronic lymphocytic leukemia; and Plogosertib, a polo-like kinase inhibitor program, which is in Phase 1/2 clinical trial for the treatment of advanced solid tumors and hematological malignancies.